GuidelineClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
SEOM-GEICAM-SOLTI clinical guidelines in advanced breast cancer (UPDATE 2025).
Guideline in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Synchronous Metaplastic Breast Carcinoma with Mesenchymal Differentiation and Triple-Negative Invasive Papillary Carcinoma: A Case Report and Literature Review.Journal of clinical medicine · 2026Article
- Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms.Molecules (Basel, Switzerland) · 2026Review
- Article
- Effects of a 12-Week Supervised Exercise Program on Quality of Life, Functional Capacity, and Biological Parameters in Women with Breast Cancer: A Prospective Pilot Program.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced breast cancer represents a challenge for patients and physicians due to its dynamic genomic changes, which are associated with resistance to treatments. The main goals of treatment in advanced breast cancer are to improve patient quality of life and to increase patient survival. This is achieved using the most appropriate sequence of treatments based on knowledge of the natural history of the disease. In these guidelines (updated in 2025), we summarize current evidence and available therapies for the medical management of advanced breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.